In yesterday’s Wall Street session, Bristol-Myers Squibb Co. (NYSE:BMY) shares traded at $50.15, down -0.91% from the previous session.
As of this writing, 28 analysts cover Bristol-Myers Squibb Co. (NYSE:BMY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $90.00 and a low of $50.00, we find $63.00. Given the previous closing price of $50.61, this indicates a potential upside of 24.48 percent. BMY stock price is now -11.36% away from the 50-day moving average and -21.63% away from the 200-day moving average. The market capitalization of the company currently stands at $102.04B.
There are 15 analysts who have given it a hold rating, whereas 10 have given it a buy rating. Brokers who have rated the stock have averaged $64.65 as their price target over the next twelve months.
With the price target of $55, Deutsche Bank recently initiated with Hold rating for Bristol-Myers Squibb Co. (NYSE: BMY).
In other news, Powell Ann, EVP, Chief Human Resources sold 17,986 shares of the company’s stock on Aug 24. The stock was sold for $1,101,642 at an average price of $61.25. Upon completion of the transaction, the EVP, Chief Human Resources now directly owns 27,868 shares in the company, valued at $1.4 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, EVP, Chief Research Officer Plenge Robert M sold 732 shares of the business’s stock. A total of $44,754 was realized by selling the stock at an average price of $61.14. This leaves the insider owning 6,584 shares of the company worth $0.33 million. Insiders disposed of 685,218 shares of company stock worth roughly $34.36 million over the past 1 year. A total of 0.16% of the company’s stock is owned by insiders.
Monday morning saw Bristol-Myers Squibb Co. (NYSE: BMY) opened at $50.45. During the past 12 months, Bristol-Myers Squibb Co. has had a low of $49.49 and a high of $81.43. As of last week, the company has a debt-to-equity ratio of 1.35, a current ratio of 1.18, and a quick ratio of 1.07. The fifty day moving average price for BMY is $56.58 and a two-hundred day moving average price translates $63.99 for the stock.
The latest earnings results from Bristol-Myers Squibb Co. (NYSE: BMY) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2, beating analysts’ expectations of $1.76 by 0.24. This compares to $0.75 EPS in the same period last year. The net profit margin was 18.44% and return on equity was 26.87% for BMY. The company reported revenue of $10.97 billion for the quarter, compared to $11.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.25 percent. For the current quarter, analysts expect BMY to generate $11.27B in revenue.
Bristol-Myers Squibb Co.(BMY) Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.